← 홈

전체 프로그램

ADC 1068 · Antibody 5456 · CGT 2744 · 다음 갱신 D-11 · 마지막 7월 13일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 1,486개
AntibodystaleRochePhase 2

trastuzumab (Herceptin, Trastuzumab combined with Pyrotinib and chemotherapy)

HER2-positive Breast Cancer · HER2

#HER2#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 RECRUITING
ADCBiologicstaleDaiichi SankyoPhase 2

trastuzumab deruxtecan (Enhertu, T-DXd, DS-8201, Trastuzumab deruxtecan-nxki)

Breast Cancer; HER2-positive Breast Cancer · HER2

#HER2#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
효능 ORR 71.7%임상시험 1상태 RECRUITING
AntibodystaleRochePreclinical

trastuzumab (Herceptin, Trastuzumab or Lapatinib)

Cancer · Cancer

#Cancer#Antibody#Preclinical#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleRochePhase 3

trastuzumab (Herceptin, Trastuzumab plus chemotherapy)

HER2-positive Breast Cancer; Metastatic Breast Cancer · HER2

#HER2#Antibody#Phase3#항체#면역항체+4
임상시험 1상태 ACTIVE
AntibodystaleRochePhase 2

trastuzumab (Herceptin, Trastuzumab+Capecitabine+Oxaliplatin)

Gastric Cancer · Gastric Cancer

#GastricCancer#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleRochePhase 2

trastuzumab (Herceptin, Trastuzumab+Nivolumab+Gemcitabine+Cisplatin)

HER2 Positive Advanced/Metastatic/Nonresectable Biliary Tract Cancer · HER2

#HER2#Antibody#Phase2#항체#면역항체+5
임상시험 1상태 RECRUITING
AntibodystaleRochePhase 2

trastuzumab (Herceptin, Trastuzumab+Pertuzumab/Trastuzumab)

Breast Cancer; Adjuvant Therapy · Breast Cancer

#BreastCancer#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 RECRUITING
AntibodystaleRochePhase 2

trastuzumab (Herceptin, Trastuzumab+pyrotinib+taxene)

Breast Cancer · Breast Cancer

#BreastCancer#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleRochePhase 2

trastuzumab (Herceptin, Trastuzumab, Pertuzumab, Paclitaxel, or a combination of these drugs)

Metastatic Breast Cancer; HER2-positive Breast Cancer · HER2

#HER2#Antibody#Phase2#항체#면역항체+4
임상시험 1상태 RECRUITING
AntibodystaleRochePhase 2

trastuzumab (Herceptin, Trastuzumab, TS ONE, Cisplatin)

HER 2 Positive Advanced Gastric Cancer · HER 2 Positive Advanced Gastric Cancer

#HER2PositiveAdvancedGastricCance#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleRochePhase 2

trastuzumab (Herceptin, Trastuzumab-rezetecan + Pertuzumab + Iparomlimab and Tuvonralimab for HER2 Moderate/Low BTC)

Biliary Tract Cancer (BTC); First-line Therapy · HER2

#HER2#Antibody#Phase2#항체#면역항체+4
임상시험 1상태 RECRUITING
AntibodystaleRochePhase 2

trastuzumab (Herceptin, Trastuzumab-rezetecan + Pertuzumab + Iparomlimab and Tuvonralimab for HER2 Overexpression BTC)

Biliary Tract Cancer (BTC); First-line Therapy · HER2

#HER2#Antibody#Phase2#항체#면역항체+4
임상시험 1상태 RECRUITING
AntibodystaleRochePreclinical

trastuzumab (Herceptin, Trastuzumab-rezetecan Treatment Group)

Trastuzumab-rezetecan; HER2-low Breast Cancer · HER2

#HER2#Antibody#Preclinical#항체#면역항체+4
임상시험 1상태 RECRUITING
ADCBiologicstaleYonsei UniversityPhase 2

Trastzumab Deruxtecan (Trastzumab Deruxtecan)

Ovarian Cancer; Ovarian Carcinoma, Recurrent · Ovarian Cancer

#OvarianCancer#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
임상시험 1상태 RECRUITING
AntibodystaleChanghai HospitalPhase 2

TURBT (Treatment with toripalimab combined with BCG perfusion following transurethral resection of bladder tumor, Treatment with toripalimab combined with BCG perfusion following transurethral resection of bladder tumor (TURBT))

Bladder Cancer · Bladder Cancer

#BladderCancer#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleAstraZenecaPhase 2

Tremelimumab monotherapy (Tremelimumab monotherapy)

Urothelial Bladder Cancer; Triple-negative Breast Cancer · Urothelial Bladder Cancer

#UrothelialBladderCancer#Antibody#Phase2#항체#면역항체+3
효능 ORR 3.1%임상시험 1상태 ACTIVE
ADCBiologicstaleChia Tai Tianqing Pharmaceutica…Phase 3

Trifluridine /Tipiracil (TAS-102, Trifluridine /Tipiracil, Trifluridine /Tipiracil (TAS-102) tablets / Fruquintinib / Regorafenib tablets)

HER2 IHC3+ Advanced Colorectal Cancer · HER2

#HER2#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+2
임상시험 1상태 RECRUITING
AntibodystaleRochePhase 2

Trifluridine-tipiracil plus Bevacizumab Alone (Trifluridine-tipiracil plus Bevacizumab Alone)

Refractory Metastatic Colorectal Cancer · FRα

#FR#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 RECRUITING
ADCBiologicstaleM.D. Anderson Cancer CenterPhase 1

TAS-102 (Trifluridine/tipiracil, Trifluridine/tipiracil (TAS-102))

Dynamic Tumor Resistance; Metastatic Colorectal Cancer · Dynamic Tumor Resistance

#DynamicTumorResistance#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+2
임상시험 1상태 RECRUITING
AntibodystaleRochePhase 2

Trifluridine/tipiracil (TAS-102, Trifluridine/tipiracil, Trifluridine/tipiracil (TAS-102) plus bevacizumab)

Colo-rectal Cancer; Third-line and Beyond Therapy · Colo-rectal Cancer

#Colo-rectalCancer#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 RECRUITING

67 / 75 페이지

← 이전다음 →